|
HMD launches India’s First Dispovan Insulin
Pen Needle
Hindustan Syringes & Medical Devices (HMD) one of the largest
manufacturers of Disposable Syringes in the World and the largest for Auto
Disable syringes has today launched most revolutionary and pioneering, India’s
First “Made in India” Dispovan Insulin Pen Needle” to provide better comfort for
people with diabetes at the 4th Medical Expo Indore 2018. The Dispovan Insulin
pen needle is a precision engineered, yet affordable sterile single use pen
needle, which can be universally fitted on all international brands of Insulin
Pens. With features like, ergonomic shape for improved skin contact and grip,
extra thin wall, multi-bevel, tapered point, Dispovan Insulin pen needle is
designed and manufactured by HMD with intent to offer a much less painful
injection experience for diabetic patients.
According to Mr. Rajiv Nath, Jt. Managing Director of
Hindustan Syringes & Medical Devices (HMD), “We are particularly excited about
the prospects of our latest offering ” Dispovan Insulin Pen Needle” manufactured
in our state of the art manufacturing facilities, which will end India’s import
dependency and the monopoly of BD. Patients will now be able to access an
affordable quality product, which they need not reuse because it is expensive.
We have received excellent feedback and clinical
acceptance from the end users of a comfortable injection and glad that our
investments in high end technology are giving us a competitive edge.”
“With the launch of ‘Dispovan Insulin Pen Needle’ we will
contribute towards our ongoing commitment of making healthcare affordable for
common people in India” said Mr. Pardeep Sareen, Chief General Manager-Marketing
of HMD.
“Why reuse a pen needle”, he quipped “when Dispovan makes it
affordable for single use? Reuse of a Insulin pen needle could increase the
following :
• Bacterial growth on the needle – Risk of injection
• Experiencing pain when injecting
• Risk of lipohypertrophy (lumpy skin) occurring
• Risk of the very fine tip of the needle breaking off
The above stated risks will grow with each reuse”, he adviced.
Dispovan Insulin Pen Needle is manufactured at HMD’s
Faridabad-Ballabgarh plant. The new plant is spread on an area of 5.5 acres and
will have the capacity to initially produce over 100 million units per annum of
‘Dispovan Insulin Pen Needle’ to meet the rising export and domestic demand for
its new technology. Every Needle point is checked online by a Digital Vision
Camera System for a defective, blunt needle point and such needles, which can be
potentially painful are rejected automatically on line, he explained. The
proprietary dry silicon coating used by us makes the needle surface slippery to
ensure comfortable injection.
Dispovan Insulin Pen Needle has needle gauge option of 31G &
32G with needle length of 5mm & 4mm respectively and comes in purple and green
colour shade to enable visual recognition of needle size.
The pricing of the Becton, Dickinson and Company (BD) pen
needle is Rs.14 MRP whereas HMD has initially kept the MRP of its’ Dispovan pen
needle for Rs.12. Dispovan pen needle is economical to patient by at least 15 %,
as compared to imported pen needles. Unlike prices of imports that are volatile
and linked to ever changing exchange rates and steady devaluation of Indian
rupee that makes imports expensive, the made in India product has relatively
stable pricing.
MTaI Asks Govt To Commit Definitive Package
On Developing Healthcare Infrastructure
The Medical Technology Association of India (MTaI) has
recommended to the government to commit a definitive package on developing
healthcare infrastructure, procurement and to increase fiscal spend to 2% of GDP
in 2020-21 and 3% by 2021-22.
The entire healthcare continuum from providers to medical
device suppliers have been hit by cash crunch due to increase in import duty,
rupee devaluation against dollar, increased transport cost in the COVID
situation due to surge prices, reduced cash flow due to non-payment of dues and
decrease in revenue due to stoppage of elective procedures.
MTaI has therefore urged the government to provide some
relief and help the healthcare sector sustain in these testing times. It has
recommended to announce special fiscal package to release all pending payments
to maintain cash flow to the providers and suppliers. It has also recommended to
increase patient affordability by reducing customs duty, health cess and GST on
medical devices which cannot be made in India in the short and medium term, with
a view to handle the COVID-19 crisis. Other
recommendations include restarting the elective surgeries in all zones, with
special initiative for transportation of patients and ensuring stringent safety
guidelines. There is also a need to bring down aviation fuel cost so that cost
of logistics in shipping devices across the country is reduced.
MTaI chairman and director general Pavan Choudary said, "In
our opinion, Aatma Nirbharta (self- reliance) in medical technology sector would
be achieved, when we can make competitive products in India. When people of
India can be treated in India without having to travel abroad and spending
precious foreign exchange, when the tertiary care facilities will expand in the
government sector too, when R&D flourishes to handle our problems as well as
respond to global opportunities, when every Indian healthcare workers gets
trained as well as his best global counterpart."
The government has expressed its intention to create a
surplus capacity in healthcare infrastructure. The plan to increase public
expenditure on healthcare and ramp up health and wellness centres in remote
areas will certainly help the needy in availing health services, especially
since India’s spend on healthcare is only 1.3 per cent of its GDP and needs
severe bolstering. There is a need to carve out a concrete plan on building
healthcare infrastructure at tertiary levels both in the government and private
sectors, create more diagnostic centres and increase procurement of antibiotics
and medical devices among others.
He further added, "We believe that spending on healthcare can
increase GDP by increasing productivity with reduced loss of man-days due to
sickness. Also healthcare investment can increase employment opportunities in
service provider segment like hospitals with increased number of clinicians,
paramedics and nurses. The employment opportunities in the industries supporting
it like medical technology and pharmaceuticals will also be increased with more
spend on manufacturing, supply chain and R&D. It is clearly established that
countries with higher spend on healthcare have better per capita income with
higher productivity." MTaI is an association of research-based medical
technology companies who have made remarkable investments in manufacturing, R&D
and health care workers training in India.
http://www.pharmabiz.com/NewsDetails.aspx?aid=124226&sid=1
|
